DISEASE NEED
Mutations in the Wnt/β-catenin pathway are responsible for millions of cases of cancer globally every year, but to date there have been no successful therapies targeting this pathway. These mutations are particularly prevalent in colorectal cancer: An estimated 80-90% of cases of colorectal cancer are caused by mutations in the Wnt/β-catenin pathway.
Colorectal cancer is the second-highest cause of global cancer deaths, according to the World Health Organization, with a toll of nearly 1 million deaths annually.
Learn more about disease needFOG-001 DESIGN
Our unique Helicon™ technology is designed to interrupt the Wnt/β-catenin pathway in a way that others have thus far been unable to do, resulting in a drug that is uniquely suited to address one of the fundamental drivers of colorectal cancer and other tumor types.
The investigational therapy FOG-001 is a first-in-class competitive inhibitor — and the only direct inhibitor — of β-catenin interactions with the T-cell factor (TCF) family of transcription factors. By directly targeting the β-catenin:TCF protein-protein interaction, the most downstream node in the Wnt pathway, FOG-001 is intended to block the Wnt signaling pathway irrespective of the particular mutations driving disease (including APC and β-catenin).
